bridgebio pharma to present updated data from its bbp-812 canavan disease gene therapy program at the 2023 american society of gene and cell therapy (asgct) annual meeting

PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease, will be presented at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, CA on May 16 – 20, 2023. Additionally, members of BridgeBio leadership, including Neil Kumar, CEO and founder, will be presenting on multiple panels discussing drug development and accelerated approval for gene therapy. Oral presentation details: Initial biomarker and clinical findings from the CANaspire Canavan disease gene therapy trial: Exploration of connections between NAA and disease severity Presenter: Florian Eichler, M.D., director of the leukodystrophy service at Massachusetts General Hospital, Center for Rare Neurological Disease and lead CANaspire investigator Session date/ time: Saturday, May 20 at 10:15 am – 12:00 pm PT Presentation time: 11:15 am – 11:30 am PT Location: Concourse Hall 150 & 151, Los Angeles Convention Center Session title: Gene and cell therapy trials in progress Abstract number: 358 Additional panel details: Accelerated approval for cell and gene therapies Date & time: Wednesday, May 17 at 9:00 am – 9:45 am PT Panelist: Adora Ndu, Pharm.D., J.D., chief regulatory and interim legal officer of BridgeBio Location: Room 515 AB, Los Angeles Convention Center Venture capital in the gene and cell therapy space Date & time: Friday, May 19 at 8:00 am – 9:45 am PT Co-chair: Eric David, M.D., J.D., CEO of BridgeBio Gene Therapy Panelist: Neil Kumar, Ph.D., founder and CEO of BridgeBio Location: Concourse Hall 152 & 153, Los Angeles Convention Center Evolution of genetic medicines: Navigating the challenges and synergies among therapeutic modalities Date & time: Friday, May 19 at 10:15 am – 12:30 pm PT Panelist: Eric David, M.D., J.D., CEO of BridgeBio Gene Therapy Location: Room 411, Los Angeles Convention Center Accelerate your drug development program in rare disease with robust natural history data: An evolving space Session title: How to design a natural history study that regulators and clinicians support Date & time: Friday, May 19 at 10:15 am – 12:00 pm PT Panelist: Adam Shaywitz, M.D., Ph.D., chief medical officer at BridgeBio Gene Therapy Location: Room 408 AB, Los Angeles Convention Center About BridgeBio Pharma, Inc. BridgeBio Pharma Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter. BridgeBio Media Contact: Vikram Bali [email protected] (650)-789-8220 View All News Stay Informed. COMPANY About Us opens in new window Careers opens in new window Investors opens in new window Legal Policies opens in new window INSIGHTS On Rare Podcast ↗ opens in new window News opens in new window SCIENCE Clinical Trial Info opens in new window Presentations & Publications opens in new window Grants & Funding opens in new window MEDICINES & PIPELINE Pipeline opens in new window Attruby® (acoramidis) ↗ opens in new window NULIBRY® (fosdenopterin) ↗ opens in new window PATIENTS Stories opens in new window Access opens in new window Support opens in new window SOCIAL LinkedIn ↗ opens in new window X ↗ opens in new window Facebook ↗ opens in new window Instagram ↗ opens in new window Youtube ↗ opens in new window Tiktok ↗ opens in new window This site is intended for U.S. residents. BridgeBio, Attruby, the Attruby logo, ForgingBridges, and the ForgingBridges logo are trademarks of BridgeBio Pharma, Inc. All other trademarks are property of their respective owners. © 2026 BridgeBio Pharma Inc. - All rights reserved Powered By Q4 Inc. 5.187.1.9 (opens in new window)

The release as fetched from its publisher. bridgebio.com ↗